Skip to site menu Skip to page content

Daily Newsletter

15 September 2023

Daily Newsletter

15 September 2023

IVX Health expands Florida presence with five new centres

These new centres are in Doral, Hallandale Beach, Kendall, South Miami, and Sweetwater.

September 15 2023

US-based outpatient infusion and injection centre provider IVX Health has strengthened its reach in Florida with five new centres in Greater Miami, bringing its total site count in the state to 27 across ten markets.

Of the five new Miami centres, the sites in Kendall, South Miami and Sweetwater are already operational while the Doral and Hallandale locations are scheduled to open soon.

The South Miami and Sweetwater centres were operating under the InfuseWell brand, before being purchased by IVX Health this month.

These centres offer private suites, along with amenities such as streaming TVs and comfortable recliners.

IVX Health regional vice-president Sean Hutchison said: “We recognise the impact these five locations will make in the lives of speciality biologic patients in Miami.

“Our care model ensures a world-class service experience and high-quality care for patients.

“Referring specialists benefit from IVX's ability to streamline the referral process by facilitating prior authorisations and benefits eligibility.

“We truly believe IVX is the easiest infusion provider for speciality practices to work with when referring patients.”

IVX Health maintains a low (1:3) nurse-to-patient ratio and adheres to hospital-level safety standards.

The company has been expanding across the US and aims to serve patients with complex chronic conditions.

It offers infusion and injection therapy for conditions such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis, among others.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Primarily due to COVID-19, the healthcare sector has witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close